Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 142.62
ARDM's Cash to Debt is ranked higher than
87% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ARDM: 142.62 )
ARDM' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 142.62

Equity to Asset 0.74
ARDM's Equity to Asset is ranked higher than
80% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ARDM: 0.74 )
ARDM' s 10-Year Equity to Asset Range
Min: -1.83   Max: 0.93
Current: 0.74

-1.83
0.93
F-Score: 6
Z-Score: -3.57
M-Score: 2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -10.86
ARDM's Operating margin (%) is ranked higher than
55% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.59 vs. ARDM: -10.86 )
ARDM' s 10-Year Operating margin (%) Range
Min: -9165.74   Max: -77.3
Current: -10.86

-9165.74
-77.3
Net-margin (%) 16.02
ARDM's Net-margin (%) is ranked higher than
89% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.31 vs. ARDM: 16.02 )
ARDM' s 10-Year Net-margin (%) Range
Min: -9007.17   Max: -76.7
Current: 16.02

-9007.17
-76.7
ROE (%) 12.72
ARDM's ROE (%) is ranked higher than
85% of the 874 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. ARDM: 12.72 )
ARDM' s 10-Year ROE (%) Range
Min: -808.13   Max: -55.03
Current: 12.72

-808.13
-55.03
ROA (%) 9.27
ARDM's ROA (%) is ranked higher than
89% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. ARDM: 9.27 )
ARDM' s 10-Year ROA (%) Range
Min: -102.39   Max: -27
Current: 9.27

-102.39
-27
ROC (Joel Greenblatt) (%) -254.71
ARDM's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.17 vs. ARDM: -254.71 )
ARDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3533.63   Max: -41.59
Current: -254.71

-3533.63
-41.59
Revenue Growth (%) -8.00
ARDM's Revenue Growth (%) is ranked higher than
55% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ARDM: -8.00 )
ARDM' s 10-Year Revenue Growth (%) Range
Min: -81.3   Max: 118.8
Current: -8

-81.3
118.8
EBITDA Growth (%) -10.90
ARDM's EBITDA Growth (%) is ranked higher than
59% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. ARDM: -10.90 )
ARDM' s 10-Year EBITDA Growth (%) Range
Min: -61.1   Max: 10.6
Current: -10.9

-61.1
10.6
EPS Growth (%) 12.20
ARDM's EPS Growth (%) is ranked higher than
78% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ARDM: 12.20 )
ARDM' s 10-Year EPS Growth (%) Range
Min: -55.6   Max: 19.8
Current: 12.2

-55.6
19.8
» ARDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARDM Guru Trades in

ARDM Guru Trades in

Q2 2014

ARDM Guru Trades in Q2 2014

Jean-Marie Eveillard 3,854,730 sh (New)
» More
Q3 2014

ARDM Guru Trades in Q3 2014

Jean-Marie Eveillard 3,854,730 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 New Buy0.08%$0.185 - $9.52 $ 7.24115%3854730
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 35.10
ARDM's P/E(ttm) is ranked higher than
79% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.00 vs. ARDM: 35.10 )
ARDM' s 10-Year P/E(ttm) Range
Min: 0.12   Max: 51.26
Current: 35.1

0.12
51.26
P/B 2.68
ARDM's P/B is ranked higher than
75% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. ARDM: 2.68 )
ARDM' s 10-Year P/B Range
Min: 0.01   Max: 5.38
Current: 2.68

0.01
5.38
P/S 3.53
ARDM's P/S is ranked higher than
74% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. ARDM: 3.53 )
ARDM' s 10-Year P/S Range
Min: 0.03   Max: 5.45
Current: 3.53

0.03
5.45
PFCF 11.31
ARDM's PFCF is ranked higher than
97% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ARDM: 11.31 )
ARDM' s 10-Year PFCF Range
Min: 11.31   Max: 28.33
Current: 11.31

11.31
28.33
Current Ratio 8.99
ARDM's Current Ratio is ranked higher than
93% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. ARDM: 8.99 )
ARDM' s 10-Year Current Ratio Range
Min: 0.94   Max: 21.99
Current: 8.99

0.94
21.99
Quick Ratio 8.99
ARDM's Quick Ratio is ranked higher than
94% of the 890 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ARDM: 8.99 )
ARDM' s 10-Year Quick Ratio Range
Min: 0.94   Max: 21.99
Current: 8.99

0.94
21.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.05
ARDM's Price/Net Cash is ranked higher than
97% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ARDM: 3.05 )
ARDM' s 10-Year Price/Net Cash Range
Min: 0.04   Max: 9.07
Current: 3.05

0.04
9.07
Price/Net Current Asset Value 3.05
ARDM's Price/Net Current Asset Value is ranked higher than
97% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ARDM: 3.05 )
ARDM' s 10-Year Price/Net Current Asset Value Range
Min: 0.04   Max: 42.08
Current: 3.05

0.04
42.08
Price/Tangible Book 2.68
ARDM's Price/Tangible Book is ranked higher than
81% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. ARDM: 2.68 )
ARDM' s 10-Year Price/Tangible Book Range
Min: 0.03   Max: 4.75
Current: 2.68

0.03
4.75
Price/Median PS Value 13.66
ARDM's Price/Median PS Value is ranked higher than
54% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. ARDM: 13.66 )
ARDM' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 27.75
Current: 13.66

0.13
27.75
Price/Graham Number 1.62
ARDM's Price/Graham Number is ranked higher than
88% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.77 vs. ARDM: 1.62 )
ARDM' s 10-Year Price/Graham Number Range
Min: 2.2   Max: 2.2
Current: 1.62

Earnings Yield (Greenblatt) -5.60
ARDM's Earnings Yield (Greenblatt) is ranked higher than
55% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ARDM: -5.60 )
ARDM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 46.1   Max: 964.4
Current: -5.6

46.1
964.4
Forward Rate of Return (Yacktman) -18.12
ARDM's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. ARDM: -18.12 )
ARDM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -105543.7   Max: -14.9
Current: -18.12

-105543.7
-14.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Aradigm Corp, a California corporation was incorporated on January 30, 1991 . It is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. The Company's development candidates include proprietary formulations of the potent antibiotic ciprofloxacin or Pulmaquin ARD-3150 and Lipoquin ARD-3100 that are delivered by inhalation for the management of infections associated with the severe respiratory diseases such as non-cystic fibrosis bronchiectasis and cystic fibrosis. Its proprietary programs under development include, Inhaled Ciprofloxacin and Smoking Cessation Therapy. Ciprofloxacin has been approved by the FDA as an anti-infective agent and is widely used for the acute treatment of a variety of bacterial infections, including exacerbations associated with pulmonary infections. ARD-1600 Inhaled Nicotine is used for Smoking Cessation Therapy. It competes with pharmaceutical and biotechnology companies, hospitals, research organizations, individual scientists and nonprofit organizations engaged in the development of drugs and other therapies for the respiratory disease indications. It had 74 issued United States patents, with 14 additional United States patent applications pending. The research, development, testing, manufacturing, labeling, advertising, promotion, distribution, marketing and export, among other things, of any products it develops are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for ARDM

Headlines

Articles On GuruFocus.com
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
ARADIGM CORP Financials Nov 15 2014
Aradigm to Present at the Stifel Healthcare Conference 2014 Nov 12 2014
Aradigm to Present at the Stifel Healthcare Conference 2014 Nov 12 2014
10-Q for Aradigm Corp. Nov 09 2014
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 07 2014
Aradigm Announces Third Quarter 2014 Financial Results Nov 07 2014
Aradigm Announces Third Quarter 2014 Financial Results Nov 07 2014
Aradigm (ARDM) Downgraded From Hold to Sell Oct 31 2014
Aradigm (ARDM) Falls: Stock Goes Down 5.2% Sep 23 2014
Aradigm (ARDM) Upgraded From Sell to Hold Sep 22 2014
Aradigm (ARDM) is in Overbought Territory: What's Next? Sep 12 2014
Aradigm Corporation (ARDM) Up: Stock Adds 9.7% in Session Sep 11 2014
FDA Grants Fast Track Designation to Aradigm’s Pulmaquin for Non-Cystic Fibrosis Bronchiectasis Sep 04 2014
ARADIGM CORP Files SEC form 10-Q, Quarterly Report Aug 11 2014
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 08 2014
Aradigm Announces Second Quarter 2014 Financial Results Aug 07 2014
Aradigm to Host Analyst Meeting and Webcast on August 12 in New York City Aug 06 2014
Aradigm to Host Corporate Update Conference Call on June 26 Jun 25 2014
ARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 09 2014
Aradigm receives $5M milestone for dosing of first patient in Phase III study Jun 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK